Streetbeat News

Analyst Ratings

MRVL

Morgan Stanley analyst Joseph Moore maintains an Equal-Weight rating on Marvell Tech (NASDAQ:MRVL) and raises the price target from $45 to $55.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 11:51 am

MSGS

Morgan Stanley analyst Benjamin Swinburne maintains an Equal-Weight rating on Madison Square Garden (NYSE:MSGS) and raises the price target from $200 to $220.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 11:50 am

ESS

Morgan Stanley analyst Chandni Luthra maintains an Equal-Weight rating on Essex Property Trust (NYSE:ESS) and lowers the price target from $246 to $228.5.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 11:50 am

EQR

Morgan Stanley analyst Adam Kramer maintains an Equal-Weight rating on Equity Residential (NYSE:EQR) and lowers the price target from $68 to $64.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 11:49 am

DLTR

Morgan Stanley analyst Simeon Gutman maintains an Equal-Weight rating on Dollar Tree (NASDAQ:DLTR) and lowers the price target from $145 to $140.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 11:49 am

AVB

Morgan Stanley analyst Adam Kramer maintains an Equal-Weight rating on AvalonBay Communities (NYSE:AVB) and lowers the price target from $190 to $180.5.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 11:48 am

CORT

Truist Securities analyst Gregory Fraser maintains a Hold rating on Corcept Therapeutics (NASDAQ:CORT) and lowers the price target from $28 to $26.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 11:47 am

ULTA

Raymond James analyst Olivia Tong maintains a Strong Buy rating on Ulta Beauty (NASDAQ:ULTA) but lowers the price target from $615 to $600.

Portfolio Pulse from richadhand@benzinga.com

May 26, 2023 | 11:46 am

DECK

Wells Fargo analyst Kate Fitzsimons maintains an Equal-Weight rating on Deckers Outdoor (NYSE:DECK) and raises the price target from $425 to $480.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 11:46 am

ARQT

Truist Securities analyst Gregory Fraser maintains a Buy rating on Arcutis Biotherapeutics (NASDAQ:ARQT) but lowers the price target from $45 to $40.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 11:45 am